Our Pricing

Wegovy Prices UK: All Doses In Stock

Published on: June 03, 2026

Finding transparent wegovy prices uk all doses can be challenging when many pharmacies hide costs behind consultation forms. At Cured Pharmacy, we display upfront pricing from £79.00 for genuine UK-licensed Wegovy semaglutide injections, with all dose strengths currently in stock and available following a free clinical assessment by our UK prescribers.

Understanding Wegovy Pricing Across All Dose Strengths

Wegovy (semaglutide) is available in five escalating dose strengths: 0.25mg, 0.5mg, 1mg, 1.7mg, and the maintenance dose of 2.4mg weekly [1]. At Cured Pharmacy, pricing starts from £79.00, with the specific cost determined by your prescribed dose following clinical assessment by a UK-registered prescriber under the supervision of our superintendent pharmacist Tarun Kumar (GPhC 2233073).

The graduated dosing schedule is clinically essential — it allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation, significantly reducing the risk of gastrointestinal side effects [1]. Most patients begin with the 0.25mg starter dose for four weeks before progressing through higher strengths over approximately 16-20 weeks to reach the therapeutic 2.4mg maintenance dose.

Unlike some online pharmacies that advertise low entry prices but increase costs dramatically at higher doses, Cured Pharmacy maintains competitive pricing throughout your treatment journey. All doses are currently in stock, eliminating the frustrating supply interruptions that have affected UK Wegovy availability since its MHRA approval in 2023.

How Wegovy Semaglutide Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone your intestines produce after eating [2]. This medication works through multiple pathways: it slows gastric emptying so you feel fuller for longer, reduces appetite signals in the brain, and improves insulin sensitivity.

The STEP clinical trial programme demonstrated Wegovy's efficacy across diverse patient populations. In the landmark STEP 1 trial, participants achieved an average 14.9% body weight reduction over 68 weeks when combining semaglutide 2.4mg with lifestyle interventions, compared to 2.4% with placebo [2]. Importantly, 86.4% of participants in the treatment group achieved at least 5% weight loss — the threshold associated with meaningful health improvements.

Clinical data shows semaglutide's effects extend beyond weight reduction. Trial participants experienced improvements in cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory markers [2]. The medication is licensed in the UK for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea.

Expected Timeline and Results

Most patients notice appetite reduction within the first week of treatment, though significant weight loss typically becomes evident after reaching higher dose strengths around weeks 8-12 [2]. The full therapeutic effect manifests at the 2.4mg maintenance dose, which you'll typically reach after 16-20 weeks of gradual dose escalation. Clinical trials measured outcomes at 68 weeks, demonstrating sustained weight loss when treatment continues alongside dietary and activity modifications.

Wegovy Dosing Schedule: What to Expect

Your Wegovy treatment follows a structured dose escalation protocol designed to optimise tolerance and efficacy. You'll begin with 0.25mg once weekly for four weeks, then progress to 0.5mg for four weeks, 1mg for four weeks, 1.7mg for four weeks, and finally the maintenance dose of 2.4mg weekly [1].

Each pre-filled pen contains four doses at the same strength, meaning you'll use one complete pen per month at each dose level. The subcutaneous injection is administered once weekly on the same day each week, into your abdomen, thigh, or upper arm. If you miss a dose by more than five days, clinical guidance recommends resuming at the next scheduled dose rather than doubling up.

Some patients experience gastrointestinal side effects — particularly nausea, diarrhoea, or constipation — most commonly during dose increases [1]. These effects typically diminish within days to weeks as your body adapts. Your UK prescriber may recommend staying at a lower dose for an additional four weeks if side effects are problematic, or in rare cases, discontinuing if symptoms persist despite slower titration.

Storage and Administration Guidance

Store unused Wegovy pens in a refrigerator between 2°C and 8°C, protected from light. Once you begin using a pen, it can remain at room temperature (below 30°C) for up to 28 days, making it convenient for travel. Never freeze Wegovy, and discard any pens that have been frozen. The injection technique is straightforward — our clinical team provides detailed administration guidance following your consultation, and Novo Nordisk supplies comprehensive patient resources with each prescription.

Comparing Wegovy to Other Weight Loss Treatments

The UK market now offers several prescription weight loss medications, each with distinct mechanisms and clinical profiles. Wegovy represents the once-weekly semaglutide option, whilst other GLP-1 treatments include daily liraglutide injections and newer dual-pathway medications that activate additional hormone receptors.

Head-to-head trial data remains limited, but indirect comparisons suggest varying efficacy profiles. The STEP trials demonstrated average weight loss of 14.9% with semaglutide 2.4mg over 68 weeks [2], whilst trials of dual-pathway treatments have shown average reductions exceeding 20% at the highest doses over 72 weeks [3]. However, individual response varies significantly — some patients respond exceptionally to one medication whilst experiencing limited benefit from another.

Oral weight loss options like orlistat work through entirely different mechanisms, blocking fat absorption in the intestines rather than affecting appetite hormones. These typically produce more modest weight reductions of 5-10% but may suit patients who prefer tablet formulations or have contraindications to injectable treatments. Your UK prescriber will assess your medical history, previous weight loss attempts, and personal preferences to recommend the most appropriate option.

Wegovy Prices UK: Why Choose Cured Pharmacy

At Cured Pharmacy, we've structured our service to address the most common frustrations UK patients report when seeking prescription weight loss treatment online. Our pricing is displayed upfront at £79.00 before you begin the consultation process — no hidden fees, no surprise costs revealed only after completing lengthy medical questionnaires.

Every prescription is assessed by UK-registered prescribers working under the supervision of our superintendent pharmacist Tarun Kumar (GPhC 2233073). The online consultation takes under three minutes for most patients and covers essential medical history including cardiovascular health, previous weight loss attempts, current medications, and contraindications. If Wegovy is clinically appropriate, your prescription is processed the same day and dispensed from our GPhC-registered pharmacy (registration number 9012511).

We guarantee 100% discreet packaging with no external branding or medication details visible on parcels. Delivery is fast and reliable, with most patients receiving their treatment within 2-3 working days via tracked courier. Our clinical team remains available throughout your treatment journey for dosing queries, side effect management, or prescription adjustments as your weight loss progresses.

Stock Availability Guarantee

Wegovy supply disruptions have frustrated UK patients since the medication's launch, with some pharmacies maintaining waiting lists stretching weeks or months. At Cured Pharmacy, we maintain stock across all five dose strengths and update availability in real-time on our website. When you complete your consultation and receive prescriber approval, your medication ships immediately — no waiting lists, no uncertain timelines.

Starting Your Wegovy Treatment: The Clinical Process

Beginning Wegovy treatment at Cured Pharmacy starts with our online clinical assessment, accessible 24/7 from any device. The consultation covers essential medical criteria: your current BMI, weight-related health conditions, cardiovascular history, previous weight loss attempts, current medications, and any contraindications to GLP-1 therapy [1].

Certain medical conditions require careful evaluation before starting semaglutide. These include personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, severe gastrointestinal disease, diabetic retinopathy complications, or pregnancy and breastfeeding [1]. Your prescriber will also assess potential drug interactions, particularly with medications that affect gastric emptying or require precise timing.

If approved, you'll receive your first prescription for the 0.25mg starter dose. Most patients continue with Cured Pharmacy for subsequent prescriptions as they progress through higher dose strengths, with our clinical team monitoring your response and adjusting treatment as needed. We recommend scheduling follow-up consultations every 8-12 weeks to assess weight loss progress, side effect management, and any necessary dose modifications. Treatment duration varies by individual goals and response, with clinical trials extending up to 68 weeks [2].

Who Should Not Use Wegovy

Wegovy is not suitable for everyone. Absolute contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, previous serious hypersensitivity to semaglutide, pregnancy, and breastfeeding [1]. Relative contraindications requiring careful risk-benefit assessment include severe renal impairment, active gallbladder disease, history of pancreatitis, and proliferative diabetic retinopathy. Your UK prescriber will evaluate your complete medical profile to determine if Wegovy is clinically appropriate for your circumstances.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, alongside reduced-calorie diet and increased physical activity.